Harmony Biosciences Holdings, Inc. — Form 8-K
Filed July 16, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
Glenn Reicin, Chief Financial Officer of Harmony Biosciences Holdings, Inc., separated from the company effective July 16, 2026, under a separation agreement providing $500,000 severance paid over 12 months, plus a $62,500 lump sum, health insurance continuation, and outplacement services, contingent on execution of a release and compliance with restrictive covenants. Stephen Mollichella, SVP and Controller, was appointed Interim Principal Financial Officer. Concurrently, the company reported record Q2 2026 WAKIX revenue of approximately $261 million (30% YoY growth, 21% QoQ growth) and reaffirmed full-year 2026 guidance of $1.0 billion to $1.04 billion.
Why this rating
CFO departure is material governance event; $562.5K severance is ~0.04% of $1.3B market cap. Revenue growth is strong, guidance maintained. Transition managed with interim replacement; no operational dispute disclosed.
See more from July 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.